Pulmonary hypertension:
Indications for: FLOLAN
Pulmonary arterial hypertension (PAH) (WHO Group I) in patients with NYHA Class III or IV symptoms, to improve exercise ability.
Adult Dosage:
Give by continuous chronic IV infusion through a central venous catheter. Initially 2ng/kg/min; increase in increments of 1–2ng/kg/min at ≥15min intervals based on response. Decrease dose gradually in 2ng/kg/min decrements at ≥15min intervals until dose-limiting effects resolve.
Children Dosage:
Not established.
FLOLAN Contraindications:
Heart failure due to reduced left ventricular ejection fraction.
FLOLAN Warnings/Precautions:
Avoid abrupt withdrawal or large dose reductions (may cause rebound pulmonary hypertension). Discontinue if pulmonary edema occurs; do not restart. Increased risk for hemorrhagic complications. Monitor BP and symptoms of vasodilation during initiation and after dose changes. Pregnancy. Nursing mothers.
FLOLAN Classification:
Prostacyclin analogue.
FLOLAN Interactions:
Hypotensive effects may be potentiated by diuretics, antihypertensive agents, other vasodilators. Increased risk of bleeding with anticoagulants, antiplatelets.
Adverse Reactions:
Dizziness, jaw pain, headache, musculoskeletal pain, nausea, vomiting, flushing.
Generic Drug Availability:
YES
How Supplied:
Vial—1 (w. diluent)
